Natalizumab and Progressive Multifocal Leukoencephalopathy: What are the causal factors? Can it be avoided?

Natalizumab (Tysabri®) was the first monoclonal antibody approved for the treatment of relapsing forms of multiple sclerosis (MS). After its initial approval, three patients undergoing natalizumab therapy in combination with other immunoregulatory and immunosuppressive agents were diagnosed with pro...

Descrizione completa

Salvato in:
Dettagli Bibliografici
Autori principali: Warnke, Clemens, Menge, Til, Hartung, Hans-Peter, Racke, Michael K., Cravens, Petra D., Bennett, Jeffrey L., Frohman, Elliot M., Greenberg, Benjamin M., Zamvil, Scott S., Gold, Ralf, Hemmer, Bernhard, Kieseier, Bernd C., Stüve, Olaf
Natura: Artigo
Lingua:Inglês
Pubblicazione: 2010
Soggetti:
Article
Accesso online:https://ncbi.nlm.nih.gov/pmc/articles/PMC4157908/
https://ncbi.nlm.nih.gov/pubmed/20697042
https://ncbi.nlm.nih.govhttp://dx.doi.org/10.1001/archneurol.2010.161
Tags: Aggiungi Tag
Nessun Tag, puoi essere il primo ad aggiungerne! !

Documenti analoghi